32196999|t|Prevalence of mild cognitive impairment in type 2 diabetes mellitus is associated with serum galectin-3 level.
32196999|a|AIMS/INTRODUCTION: Galectin-3 (Gal3) contributes to insulin resistance, inflammation and obesity, the three risk factors for mild cognitive impairment (MCI) in type 2 diabetes mellitus patients. MATERIALS AND METHODS: A total of 134 hospitalized type 2 diabetes mellitus patients were assessed by the Montreal Cognitive Assessment method, and divided into 65 MCI and 69 controls. Levels of variables, Gal3 and Abeta42, were investigated in relation with cognitive function in both type 2 diabetes mellitus patients with MCI and high-fat diet/streptozotocin induced type 2 diabetes mellitus rats. RESULTS: Significantly higher levels of serum Gal3 and lower levels of plasma Abeta42 (all P < 0.05) were found in the MCI type 2 diabetes mellitus group as compared with the non-MCI type 2 diabetes mellitus control. Partial correlation analysis showed that Gal3 is negatively correlated with both MMSE score (r = -0.51, P < 0.01) and Montreal Cognitive Assessment score (r = -0.47, P < 0.001) after adjustment for glycated hemoglobin, homoeostasis model assessment of insulin resistance and Abeta42 in all type 2 diabetes mellitus patients, with a stronger effect seen in the MCI type 2 diabetes mellitus group after further analysis with MCI strata. A simple logistic regression model showed that Gal3 and Abeta42 are significantly associated with MCI type 2 diabetes mellitus patients after adjustment with the covariates sex, age, body mass index, glycated hemoglobin, homoeostasis model assessment of insulin resistance and antidiabetic drugs. Serum and brain Gal3 levels were significantly increased in high-fat diet/streptozotocin diabetic rats, which correlate to the impairment of learning and memory ability. Gal3 inhibitor modified citrus pectin decreased serum and brain Gal3 levels in diabetic rats, accompanied by the amelioration of learning and memory impairment. CONCLUSIONS: Gal3 might be associated with cognitive impairment in type 2 diabetes mellitus, and serum Gal3 level might be a new risk factor of MCI in type 2 diabetes mellitus patients.
32196999	19	39	cognitive impairment	Disease	MESH:D003072
32196999	43	67	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	93	103	galectin-3	Gene	3958
32196999	130	140	Galectin-3	Gene	3958
32196999	142	146	Gal3	Gene	3958
32196999	163	181	insulin resistance	Disease	MESH:D007333
32196999	183	195	inflammation	Disease	MESH:D007249
32196999	200	207	obesity	Disease	MESH:D009765
32196999	241	261	cognitive impairment	Disease	MESH:D003072
32196999	263	266	MCI	Disease	MESH:D060825
32196999	271	295	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	296	304	patients	Species	9606
32196999	357	381	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	382	390	patients	Species	9606
32196999	470	473	MCI	Disease	MESH:D060825
32196999	512	516	Gal3	Gene	3958
32196999	521	528	Abeta42	Gene	351
32196999	592	616	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	617	625	patients	Species	9606
32196999	631	634	MCI	Disease	MESH:D060825
32196999	653	667	streptozotocin	Chemical	MESH:D013311
32196999	676	700	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	701	705	rats	Species	10116
32196999	753	757	Gal3	Gene	3958
32196999	785	792	Abeta42	Gene	351
32196999	826	854	MCI type 2 diabetes mellitus	Disease	MESH:D003924
32196999	886	914	MCI type 2 diabetes mellitus	Disease	MESH:D003924
32196999	965	969	Gal3	Gene	3958
32196999	1176	1194	insulin resistance	Disease	MESH:D007333
32196999	1199	1206	Abeta42	Gene	351
32196999	1214	1238	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	1239	1247	patients	Species	9606
32196999	1284	1312	MCI type 2 diabetes mellitus	Disease	MESH:D003924
32196999	1347	1350	MCI	Disease	MESH:D060825
32196999	1406	1410	Gal3	Gene	3958
32196999	1415	1422	Abeta42	Gene	351
32196999	1457	1485	MCI type 2 diabetes mellitus	Disease	MESH:D003924
32196999	1486	1494	patients	Species	9606
32196999	1613	1631	insulin resistance	Disease	MESH:D007333
32196999	1672	1676	Gal3	Gene	83781
32196999	1730	1744	streptozotocin	Chemical	MESH:D013311
32196999	1745	1753	diabetic	Disease	MESH:D003920
32196999	1754	1758	rats	Species	10116
32196999	1783	1824	impairment of learning and memory ability	Disease	MESH:D007859
32196999	1826	1830	Gal3	Gene	83781
32196999	1850	1863	citrus pectin	Chemical	MESH:C586814
32196999	1890	1894	Gal3	Gene	83781
32196999	1905	1913	diabetic	Disease	MESH:D003920
32196999	1914	1918	rats	Species	10116
32196999	1955	1985	learning and memory impairment	Disease	MESH:D007859
32196999	2000	2004	Gal3	Gene	3958
32196999	2030	2050	cognitive impairment	Disease	MESH:D003072
32196999	2054	2078	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	2090	2094	Gal3	Gene	3958
32196999	2131	2134	MCI	Disease	MESH:D060825
32196999	2138	2162	type 2 diabetes mellitus	Disease	MESH:D003924
32196999	2163	2171	patients	Species	9606
32196999	Negative_Correlation	MESH:C586814	MESH:D003920
32196999	Negative_Correlation	MESH:C586814	MESH:D007859
32196999	Association	MESH:D060825	3958
32196999	Association	MESH:D009765	3958
32196999	Positive_Correlation	MESH:D007859	83781
32196999	Association	MESH:C586814	MESH:D003924
32196999	Association	MESH:D007333	3958
32196999	Association	MESH:D007249	3958
32196999	Positive_Correlation	MESH:D013311	MESH:D003924
32196999	Negative_Correlation	MESH:C586814	83781
32196999	Association	MESH:D003924	3958
32196999	Positive_Correlation	MESH:D013311	MESH:D007859
32196999	Positive_Correlation	MESH:D013311	83781
32196999	Negative_Correlation	MESH:D003924	351
32196999	Association	MESH:D003072	3958
32196999	Positive_Correlation	MESH:D003920	83781

